Entyvio Disease Interactions

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Health care professionals should monitor patients for any new sign or symptom suggestive of PML. Therapy dosing should be withheld immediately and an appropriate diagnostic evaluation should be performed at the first sign or symptom suggestive of PML.

Elevated transaminase levels with or without elevated bilirubin have occurred in patients who received vedolizumab. Care should be exercised when using this agent in patients predisposed to liver injury. Do not use vedolizumab in patients with jaundice or other evidence of significant liver injury.

Prior to initiating treatment with vedolizumab, all patients should be brought up to date with all immunizations per current immunization guidelines. Patients receiving vedolizumab may receive non-live vaccines (e.g., influenza vaccine injection) and may receive live vaccines if the benefits outweigh the risks. Caution and close monitoring is recommended as there are no data on the secondary transmission of infection by live vaccines in patients receiving vedolizumab.